Business
Ludwig Enterprises Announces Brand Name for Groundbreaking Nutraceutical
Ludwig Enterprises Announces Brand Name for Groundbreaking Nutraceutical.
About this update from Ludwig Enterprises, Inc.
[{"type":"text","content":"SPARKS, NV / ACCESSWIRE / March 9, 2023 / Ludwig Enterprises, Inc. (OTC PINK:LUDG), Ludwig -The Genomics Language Company™ and its subsidiary mRNAforLife, Inc. is pleased to announce the brand name for its, soon to be launched, nutraceutical that has been formulated to reduce chronic inflammation. The product, branded NuGenea™, has been created using 20 ingredients that have been shown, in independent preclinical and clinical studies, to impact biomarkers called cytokines and chemokines that potentially cause chronic inflammation."We are very excited about the launch of NuGenea," said Dr. Marvin S. Hausman, MD, Chief Medical Officer of Ludwig Enterprises and one of the researchers who identified the significance of NuGenea's ingredients. "The World Health Organization has concluded that 50% of the world's deaths are a result of illnesses that have chronic inflammation as a causation. We may be on the brink of having the first scientifically designed nutritional tool to fight chronic inflammation and potentially prevent the development of chronic illnesses like COPD, diabetes, heart disease and many cancers.""The brand was developed using the Greek word Genea which means ‘birth'," added Luke Fannon Ludwig's consultant executing the product's launch plan. "NuGenea means "New Birth", which I believe clearly communicates our vision for the impact that this product can have by potentially improving the health and quality of life of the world's population."Ludwig Enterprises is finalizing packaging and other details in preparation for the sale of NuGenea in the second quarter of 2023. Initially Ludwig plans to have the product available for sale through Amazon Prime and on the company's website which will be launched soon.About Ludwig Enterprises, Inc.Ludwig Enterprises, Inc. is a healthcare holding company focused on cutting edge mRNA genomic technology, therapeutics and nutraceuticals. Through its subsidiary Precision Genomics it has a patent pending on the mRNA Inflammatory Index™ that measures 48 different biomarkers of inflammation. Combined with AI and deep machine learning this technology may enable healthcare professionals to identify sources of chronic inflammation and potentially prevent chronic illnesses such as diabetes, COPD, heart disease and cance...